新型抗菌药DIS-73285对多重耐药和广泛耐药淋球菌具有高体外活性
该研究评估了新型小分子抗菌药DIS-73285对262株地理、时间和遗传多样性临床淋球菌分离株及参考株(含高水平耐药、MDR和XDR株)的体外活性。结果显示DIS-73285的MIC范围为≤0.001至0.004 mg/L,MIC50、MIC90和众数MIC均≤0.001 mg/L,活性显著优于现有或既往治疗药物,且与这些药物的MIC无相关性。
要点
- DIS-73285对包括MDR和XDR在内的所有受试淋球菌株均显示高体外活性。
- 其MIC50、MIC90和众数MIC均≤0.001 mg/L,为测试的最低值。
- DIS-73285的MIC与现有或既往治疗抗菌药的MIC无相关性。
核心结论
- 新型小分子抗菌药DIS-73285对所有受试淋球菌分离株均表现出高体外效力。
研究设计与样本
- 研究采用琼脂稀释法测定DIS-73285对262株临床淋球菌分离株和参考株的MIC。
- 受试菌株包括各种类型的高水平耐药、MDR和XDR淋球菌分离株。
- 对照药物头孢曲松、头孢克肟、阿奇霉素、环丙沙星、氨苄西林、大观霉素和四环素的MIC通过Etest测定。
主要发现
- DIS-73285的MIC范围为≤0.001至0.004 mg/L。
- DIS-73285的MIC50、MIC90和众数MIC均≤0.001 mg/L(测试的最低MIC)。
- DIS-73285的活性显著优于任何当前或既往使用的治疗抗菌药。
- 未观察到DIS-73285的MIC与任何当前或既往使用抗菌药的MIC之间存在相关性。
临床怎么用
- DIS-73285作为针对泌尿生殖道和生殖道外淋病的潜在疗法,需进一步开展体外和体内研究评估其疗效、耐药出现、药代动力学/药效学参数、毒性及安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The rising incidence of antimicrobial resistance in Neisseria gonorrhoeae may result in untreatable gonorrhoea in certain circumstances and development of novel antimicrobials is urgently needed. OBJECTIVES: To evaluate the in vitro activity of a novel small-molecule antimicrobial with a new mechanism of action, DIS-73285, against a large geographically, temporally and genetically diverse collection of clinical N. gonorrhoeae isolates and reference strains, including various types of high-level resistant, MDR and XDR gonococcal isolates (n = 262). METHODS: MICs (mg/L) of DIS-73285 were determined by agar dilution and by Etest for ceftriaxone, cefixime, azithromycin, ciprofloxacin, ampicillin, spectinomycin and tetracycline. RESULTS: DIS-73285 was substantially more potent than any of the currently or previously used therapeutic antimicrobials, with MICs ranging from ≤0.001 to 0.004 mg/L, and the MIC50, MIC90 and modal MIC all ≤0.001 mg/L (lowest MIC tested). No correlation with the MICs of DIS-73285 and the MICs of any of the currently or previously used antimicrobials was observed. CONCLUSIONS: The novel chemotype, small-molecule antimicrobial DIS-73285, demonstrated high in vitro potency against all tested N. gonorrhoeae isolates. Further in vitro and in vivo studies, evaluating efficacy, resistance emergence, pharmacokinetic/pharmacodynamic parameters, toxicity and safety, should be conducted to evaluate DIS-73285 as a therapy specifically for urogenital and extra-genital gonorrhoea.
引用
- Jacobsson S, Mason C, Khan N, et al. High in vitro activity of DIS-73285, a novel antimicrobial with a new mechanism of action, against MDR and XDR Neisseria gonorrhoeae. J Antimicrob Chemother. 2020. PMID: 32712655. doi:10.1093/jac/dkaa322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。